BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18778171)

  • 1. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
    Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
    Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death.
    Navaratnam S; Kliewer EV; Butler J; Demers AA; Musto G; Badiani K
    Lung Cancer; 2010 Oct; 70(1):110-5. PubMed ID: 20153911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
    Grossi F; Tiseo M
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and lung cancer clinical trials.
    Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP
    Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
    Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
    Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.
    Higgins K; Chino JP; Marks LB; Ready N; D'Amico TA; Clough RW; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1462-7. PubMed ID: 19467798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
    Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL
    Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survivors in stage IV non-small cell lung cancer.
    Okamoto T; Maruyama R; Shoji F; Asoh H; Ikeda J; Miyamoto T; Nakamura T; Miyake T; Ichinose Y
    Lung Cancer; 2005 Jan; 47(1):85-91. PubMed ID: 15603858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
    Rusthoven KE; Hammerman SF; Kavanagh BD; Birtwhistle MJ; Stares M; Camidge DR
    Acta Oncol; 2009; 48(4):578-83. PubMed ID: 19373699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
    Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.